Lake Street raised the firm’s price target on Journey Medical (DERM) to $13 from $9 and keeps a Buy rating on the shares after the company reported Q2 revenue higher than the firm’s estimate and consensus. Though it is still early, signals from the ongoing launch of Emrosi “appear quite positive,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: